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This review discusses each component of the PFT and provides a basic guide to interpretation by using an illustrative case.
Mr Smith is a 50-year-old man who presents to his primary care physician with increased exertional dyspnea, rash, and muscle weakness for the past 6 months. He has not experienced such dyspnea before, so his physician orders a PFT. The test results are summarized in Table 1 .
SPIROMETRY
The most basic and useful PFT is spirometry. It includes measurement of exhaled or inhaled air during forced maneuvers. The forced vital capacity (FVC) is the amount of air that can be forcefully expelled, beginning with the lungs completely full (at total lung capacity [TLC] ) and blowing maximally until as empty as possible (at residual volume [RV] ). The forced expiratory volume in the first second (FEV 1 ) is the amount expelled during the first second of the FVC maneuver. The ratio of FEV 1 and FVC (FEV 1 /FVC) is used as an indicator of obstruction. The forced expiratory flow at 25% to 75% of the pulmonary volume was developed as an indicator of "small airway disease"; however, it is nonspecific. Many laboratories no longer report it, and we do not recommend using it for interpretation.
The graphic display from spirometry is typically called a flow-volume curve if it includes only expiratory flow or a flow-volume loop if it includes both expiratory and inspiratory maneuvers (for simplicity, the rest of this review refers only to the flow-volume loop). 6 The flow-volume loop provides important clues about the quality, acceptability, and reproducibility of the maneuver, which is determined by national standards and controlled by each individual laboratory. It can also indicate unusual abnormalities, such as obstructive lesions of the central airways. Inspiratory flows are disproportionately reduced by lesions of the upper (extrathoracic) airway. Conversely, lesions in the lower trachea and main stem bronchi primarily affect expiratory flows whereas a plateau on both the inspiratory and expiratory curves suggests a fixed lesion. Figure 1 illustrates common examples of flow-volume loops and associated abnormalities. 6 The abnormal results of spirometry separate into 2 large classes of disorders: obstructive and restrictive. Obstructive disorders are suggested by a low FEV 1 /FVC ratio, whereas restrictive disorders are suggested by a normal FEV 1 /FVC ratio with a low FVC. The American Thoracic Society (ATS) and European Respiratory Society (ERS) define an obstructive process as a FEV 1 /FVC ratio below the 5th percentile of the predicted value, often called the lower limit of normal (LLN). 7 Spirometry is essential for the diagnosis of obstructive processes including chronic obstructive pulmonary disease (COPD) and asthma. In obstructive disorders, the FEV 1 / FVC ratio is reduced. The severity of obstruction is quantified by the degree of reduction in FEV 1 (expressed as a percentage of the predicted normal value), which is derived from a reference population of normal individuals and calculated using height, age, sex, and ethnicity or race (Table 2) . 7 In patients with obstruction, FVC may be normal but can be reduced in individuals with "air trapping," meaning air that would not come out of the lungs during the FVC maneuver, usually because of airway collapse at low lung volumes.
A bronchodilator, such as albuterol, is often administered during spirometry so that airway responsiveness can be assessed. The degree of bronchodilator response may be expressed as a percent increase or absolute increase (in milliliters) or both as compared with the pre-bronchodilator value. The ATS defines a marked bronchodilator response as an increase of 200 mL and 12% (must meet both criteria) in FVC or FEV 1 . 7 It has some discriminative value to distinguish asthma from COPD and some predictive value for the risk of exacerbations of COPD and asthma as well as for the expected rate of decline in lung function. 14, 15 Despite this, it has poor reproducibility and its diagnostic value is limited.
The maximal voluntary ventilation (MVV) is a measure of the patient's ability to breathe in and out as deeply and rapidly as possible. It is included as part of routine spirometry by some, but not all, laboratories. A normal value is approximately 40 times the FEV 1 , and the lower limit is about 30 times the FEV 1 . 4 A decrease in MVV may be due to upper airway obstruction, neuromuscular weakness, or poor test performance. 6 If neuromuscular weakness is suspected, measurement of maximal respiratory pressures can be helpful. Likewise, if upper airway obstruction is suspected, evaluation of the inspiratory portion of the flow-volume loop may be revealing.
Mr Smith's spirometry reports a severely reduced FEV 1 and FVC (both <40% of normal) with the normal FEV 1 /FVC ratio. His MVV is also disproportionately decreased, so maximal respiratory pressures are measured and are reduced (maximal respiratory pressures are not presented in Table 1 ).
LUNG VOLUMES
Although spirometry provides much useful information about lung function, it does not measure the total amount of air in the lungs at maximal inspiration, known as TLC. It also does not measure the amount of air left in the lungs after maximal expiration, known as RV, or the volume of the lungs at which the outward recoil of the resting chest wall is counterbalanced by the inward recoil of the lungs, known as functional residual capacity. Although many laboratories report functional residual capacity, we find it too variable to provide a diagnostic value.
There are several methods available to make these measurements, including body plethysmography, helium (or inert gas) dilution, and 10 To perform this test, the patient sits in a sealed box and changes in pressure and volume are measured during a series of respiratory maneuvers. Helium (or inert gas) dilution involves the calculation of lung volumes after the patient breathes to reach the equilibrium with a known volume and concentration of helium. The nitrogen washout technique involves volume calculations based on the expired volume and concentration of nitrogen while breathing 100% oxygen.
Measurement of lung volumes is helpful for patients whose spirometry suggests restriction (reduced FVC, but normal FEV 1 /FVC ratio). A restrictive disorder is characterized by a TLC below the LLN and can be seen in patients with interstitial lung disease, neuromuscular weakness, or chest wall limitation (such as obesity). 7 The severity of restriction may be based on the decrease in TLC or, alternatively, FVC if no lung volumes are performed (but a previous PFT documented a TLC below the LLN). One way of grading the severity of restriction is presented in Table 3 .
Of all patients whose spirometry suggests restriction, only about half will have a reduced TLC (unpublished data, 2018). The remainder have a normal TLC in what we call a "nonspecific pattern" (low FEV 1 and FVC, normal FEV 1 /FVC ratio, and normal TLC), which is a pattern seen in about 10% of all complete PFTs. About 50% to 60% of patients with a nonspecific pattern have evidence of obstruction (eg, "scooping" of the expiratory flowvolume curve, increased airway resistance, and clinical evidence of an obstructive disorder), while the remaining 40% to 50% have chest wall limitation, muscle weakness, or poor performance. 16, 17 If a nonspecific pattern is found and is not consistent with obstruction, measurement of maximal respiratory pressures can be used to identify neuromuscular weakness. Imaging of the chest often clarifies the nature of other contributing factors, such as chest wall deformity, obesity, heart failure, mass lesion, or pleural effusion. If these are thought to be due to poor test performance, a repeat test by another experienced technologist is sometimes useful.
In obstructive disorders, measurement of lung volumes may be helpful to identify "air trapping," indicated by an increased RV and RV/TLC ratio, or less commonly "hyperinflation," meaning a TLC well above the upper limit of normal. The ATS/ERS guidelines do not provide reference values or discuss these abnormalities. In fact, measurement of lung volumes in patients with obstructive disorders has somewhat limited value, because most diagnoses and clinical decision making use spirometry results plus imaging, with relatively little contribution from lung volumes. 18 Some individuals will have both obstruction and restriction, a so-called mixed disorder. This is indicated by a low TLC (hence restriction) plus a low FEV 1 /FVC ratio. Although the mixed pattern is well known, it accounts for just over 1% of complete PFTs in our laboratory (P.D. Scanlon, MD, unpublished data, December 2017). It can be caused by a single disorder that causes a mixed pattern, such as cystic fibrosis, sarcoidosis, Langerhans cell histiocytosis, or heart failure, or, more commonly, the combination of an obstructive disorder, such as COPD, and a restrictive disorder, such as pulmonary fibrosis.
DIFFUSING CAPACITY OF LUNG FOR CARBON MONOXIDE
The third component of the PFT is DLCO, which is used as a measure of gas exchange, sometimes in conjunction with pulse oximetry at rest or during exercise. This is determined using the single-breath method, in which the patient exhales to RV and then inhales a vital capacity of air with small concentrations of carbon monoxide and helium or other inert gas. At maximal inspiration, the patient holds his or her breath for 10 seconds and then exhales quickly. Exhaled gas is sampled to determine concentrations of helium and carbon monoxide as a function of exhaled volume. From that, alveolar volume and DLCO are calculated. The DLCO is decreased if anemia is present, so it is often adjusted to a "corrected" value (if hemoglobin is available). The DLCO can be adversely affected by reductions in lung volume as well as various pulmonary parenchymal diseases (such as interstitial lung diseases and emphysema) or pulmonary vascular disorders (such as pulmonary hypertension).
The DLCO can be increased as well. In most cases, this is due to asthma or obesity or may be due to measurement during a nonresting state. Less common causes include pregnancy, current smoking status, diffuse alveolar hemorrhage, polycythemia, early heart failure, or left-to-right shunt. 19 The DLCO for Mr Smith is moderately reduced. Mr Smith's lung volumes reveal a TLC 64% of normal, suggesting a mild restrictive process. However, unlike most patients with a parenchymal restrictive disorder, his RV is increased and his FVC is disproportionately severely reduced compared to his TLC.
SPECIAL CASES
Typical obstructive and restrictive patterns are commonly identified by PFTs. However, there are frequent cases that do not fit the standard patterns of obstruction and restriction, such as the previously discussed "nonspecific pattern." A second recently described process is called complex restriction. This occurs when TLC is low (ie, a restrictive process), and FVC is reduced disproportionately compared with TLC (>10% lower than TLC). 20 A study of 200 such cases found that patients with complex restriction are more often female and younger than those with typical restrictive processes. The conditions most commonly associated with complex restriction include (in decreasing order) atelectasis, diaphragmatic paralysis, radiographic evidence of small airway disease, obesity, underweight, and neuromuscular weakness. 20 These should be considered, along with poor test performance, when FVC is reduced out of proportion to TLC in the absence of obstruction.
BASIC GUIDE TO INTERPRETATION
Now that the basic mechanisms behind the PFT have been explained, one way to consider interpretation of these tests is provided in Figure 2 and the accompanying text. 6 Obstructive Pathway 1. First, examine the flow-volume loop and decide whether it looks like an obstructive pattern ("scooping" of the expiratory flowvolume curve) or a restrictive pattern (a tall, narrow, or "peaked" expiratory flowvolume curve, sometimes described as a "witch's hat") or if a variable or fixed obstruction is present by looking for flattening of the inspiratory or expiratory portions of the loop. Refer to Figure 1 for examples of these abnormalities. 2. If FEV 1 /FVC is low and FVC is normal or high, simple obstruction is present. 3. If FVC is low, check TLC. 4. A low TLC suggests superimposed restriction (a mixed abnormality), while a high TLC suggests "air trapping". 5. For patients with obstruction, the response to a bronchodilator may be assessed to determine whether FEV 1 or FVC meets criteria for a positive response (a 12% improvement with an absolute increase of 200 mL).
6. The severity of obstruction is graded on the basis of the FEV 1 percent predicted (see Table 2 ). 7, 8, 13 The cutoff points for mild, moderate, and severe obstruction are arbitrary (not based on solid evidence) and vary among standards. Some standards interpret using the post-bronchodilator value (such as current ATS guidelines). 7 Others use the pre-bronchodilator value. 7. In current or former smokers with obstruction, a low DLCO suggests emphysema or other pulmonary parenchymal or vascular disorder. A normal DLCO may suggest asthma or bronchitis. 16, 17 This can be distinguished by measurement of airway resistance. An increased airway resistance suggests obstruction, whereas a normal airway resistance suggests an alternative cause (see point 13). 11. If restriction is present, severity can be graded on the basis of the TLC percent predicted (see Table 3 Mr Smith's PFT suggests a "complex restrictive" process. His TLC is mildly reduced and the FEV 1 /FVC ratio is normal, consistent with a restrictive process. His FVC is disproportionately severely decreased, out of proportion to TLC. In light of the recent study, this suggests an additional process, which might include chest wall limitation, neuromuscular weakness, poor performance, or occult obstruction. Given his reduced MVV and maximal respiratory pressures, neuromuscular weakness is favored, especially in the setting of his subjective muscle weakness. With further evaluation, he was found to have dermatomyositis as the cause of his symptoms.
Restrictive Pathway

CONCLUSION
Pulmonary function tests are essential to the diagnosis of many lung conditions and help to identify numerous nonpulmonary disease processes. Understanding the basic interpretation of the components of this valuable test is crucial for primary care physicians to aid in the diagnosis of patients with respiratory symptoms. 
